Electroconvulsive therapy protocol adaptation during the COVID-19 pandemic.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 Nov 2020
Historique:
received: 06 05 2020
revised: 26 06 2020
accepted: 30 06 2020
pubmed: 23 7 2020
medline: 10 9 2020
entrez: 23 7 2020
Statut: ppublish

Résumé

During the COVID-19 pandemic, electroconvulsive therapy units have had to confront challenges such as the infectious hazard due to aerosol-generating ventilation, or the lack of staff and material resources. Our objective was to elaborate a protocol to make ECT during the COVID-19 pandemic a safer procedure for patients and professionals. A multidisciplinary workgroup (including mental health, anesthesia, preventive medicine, and occupational risk professionals) was formed in the Hospital Clínic de Barcelona, in March 2020. A core group conducted a review of the scientific literature and healthcare organizations' guidelines and wrote a protocol draft. Then, a discussion with the workgroup was made until consensus was reached. The protocol has been continuously updated. Discussions were made by group e-mailing and video conferencing. The protocol includes the following main areas: (1) ECT unit's structural and functional considerations; (2) SARS-CoV-2 screening protocol; (3) ECT clinical practice adaptation (personal protective equipment, airway management, recovery room, and maintenance of the facilities); (4) management of COVID-19 cases; and (5) protocol assessment. The literature review was not systematic; the consensus was not based on a structured methodology. For other ECT units, local advisories may not be valid, and resource shortages (such as anesthetist availability, or the lack of respirators and PCR tests) may impede or prevent their implementation. During the COVID-19 pandemic, ECT should continue to be advocated as an essential medical procedure. It is recommended that each ECT unit develop its own protocol. This proposal may be used as a reference.

Sections du résumé

BACKGROUND BACKGROUND
During the COVID-19 pandemic, electroconvulsive therapy units have had to confront challenges such as the infectious hazard due to aerosol-generating ventilation, or the lack of staff and material resources. Our objective was to elaborate a protocol to make ECT during the COVID-19 pandemic a safer procedure for patients and professionals.
METHODS METHODS
A multidisciplinary workgroup (including mental health, anesthesia, preventive medicine, and occupational risk professionals) was formed in the Hospital Clínic de Barcelona, in March 2020. A core group conducted a review of the scientific literature and healthcare organizations' guidelines and wrote a protocol draft. Then, a discussion with the workgroup was made until consensus was reached. The protocol has been continuously updated. Discussions were made by group e-mailing and video conferencing.
RESULTS RESULTS
The protocol includes the following main areas: (1) ECT unit's structural and functional considerations; (2) SARS-CoV-2 screening protocol; (3) ECT clinical practice adaptation (personal protective equipment, airway management, recovery room, and maintenance of the facilities); (4) management of COVID-19 cases; and (5) protocol assessment.
LIMITATIONS CONCLUSIONS
The literature review was not systematic; the consensus was not based on a structured methodology. For other ECT units, local advisories may not be valid, and resource shortages (such as anesthetist availability, or the lack of respirators and PCR tests) may impede or prevent their implementation.
CONCLUSIONS CONCLUSIONS
During the COVID-19 pandemic, ECT should continue to be advocated as an essential medical procedure. It is recommended that each ECT unit develop its own protocol. This proposal may be used as a reference.

Identifiants

pubmed: 32697705
pii: S0165-0327(20)32448-4
doi: 10.1016/j.jad.2020.06.051
pmc: PMC7361096
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-248

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Références

J ECT. 2020 Jun;36(2):80-85
pubmed: 32433119
Lancet Psychiatry. 2020 Jun;7(6):468-471
pubmed: 32330430
JAMA Psychiatry. 2020 Sep 1;77(9):891-892
pubmed: 32242888
BMJ. 2020 Mar 16;368:m1071
pubmed: 32179567
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
JAMA Psychiatry. 2020 Nov 1;77(11):1093-1094
pubmed: 32275300
J Affect Disord. 2020 Mar 1;264:318-323
pubmed: 32056767
Psychiatry Res. 2010 Feb 28;175(3):280-3
pubmed: 20034675
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549
Am J Geriatr Psychiatry. 2020 Jul;28(7):772-775
pubmed: 32345550
Prehosp Disaster Med. 2020 Jun;35(3):305-313
pubmed: 32138799
J ECT. 2020 Jun;36(2):86-87
pubmed: 32433120
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003
Biol Psychiatry. 2020 Oct 1;88(7):e33-e34
pubmed: 32381276
JAMA Psychiatry. 2020 Oct 1;77(10):989-990
pubmed: 32275289
Rev Psiquiatr Salud Ment (Engl Ed). 2020 Apr - Jun;13(2):105-110
pubmed: 32376131
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
J ECT. 2020 Jun;36(2):78-79
pubmed: 32433118
Rev Psiquiatr Salud Ment. 2015 Apr-Jun;8(2):51-4
pubmed: 25682946
Acta Psychiatr Scand. 2020 May;141(5):479-480
pubmed: 32279309
N Engl J Med. 2020 Apr 30;382(18):1721-1731
pubmed: 32348643
Ann Surg. 2020 Jul;272(1):e27-e29
pubmed: 32221117
J Neurosurg Anesthesiol. 2020 Jul;32(3):202-209
pubmed: 32301764
Anaesthesia. 2020 Jun;75(6):785-799
pubmed: 32221970
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Acta Psychiatr Scand. 2017 Dec;136(6):583-593
pubmed: 28922451
Lancet Infect Dis. 2020 May;20(5):e102-e107
pubmed: 32145768
J Affect Disord. 2020 May 15;269:201-202
pubmed: 32339137
Int J Biol Sci. 2020 Mar 15;16(10):1741-1744
pubmed: 32226293
Rev Psiquiatr Salud Ment (Engl Ed). 2020 Jan - Mar;13(1):36-46
pubmed: 30078550
Schizophr Res. 2016 Mar;171(1-3):215-24
pubmed: 26827129
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930

Auteurs

Joaquín Gil-Badenes (J)

Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain.

Ricard Valero (R)

Department of Anaesthesiology, Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Marc Valentí (M)

Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Elisabet Macau (E)

Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain.

Maria Jesús Bertran (MJ)

Preventive Medicine and Epidemiology Department, Hospital Clínic de Barcelona, Catalonia, Spain; Clínic Institute of Medicine and Dermatology (ICMiD), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain.

Gerard Claver (G)

Occupational Health Services, Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain.

Miquel Bioque (M)

Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Inmaculada Baeza (I)

Department of Child and Adolescent Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Anna Bastidas Salvadó (A)

Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

María Lombraña Mencia (M)

Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Isabella Pacchiarotti (I)

Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Miquel Bernardo (M)

Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain.

Eduard Vieta (E)

Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona, Catalonia, Spain; Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Catalonia, Spain; Institute of Neuroscience (ICN), Hospital Clínic de Barcelona, Catalonia, Spain; Hospital Clínic de Barcelona, 170 Villarroel St., 08036 Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; University of Barcelona, 08036 Barcelona, Catalonia, Spain. Electronic address: evieta@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH